(Reuters) German pharmaceuticals company Bayer AG has entered a new cancer partnership with Israel's Compugen Ltd. to research, develop and commercialize antibody-based therapies. Under the deal, Compugen is eligible to receive over $500 million in potential milestone payments. Antibody-based immunotherapy aims at combating cancer by stimulating the body's own immune cells. Compugen said it has discovered two novel immune checkpoint regulators. Its researchers are developing specific therapeutic antibodies to reactivate the patient's anti-tumor immune response in order to fight cancer.
2013-08-09 00:00:00Full ArticleBACK Visit the Daily Alert Archive